The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Power List / 2026 / Power List / Sinchita Roy-Chowdhuri

Sinchita Roy-Chowdhuri

Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

  • Q&A

About Sinchita Roy-Chowdhuri

What gaps in technology/training/processes concern you most, and how are you addressing them via innovation?

No Patient Left Behind

Current therapeutic management of patients with solid tumors is largely dependent on molecular diagnostics and being able to identify genomic alterations in tissue specimens that drive precision oncology. In patients with advanced stage malignancies where diagnoses are typically made on small specimens, 10–20 percent of patients cannot get molecular profiling due to insufficient tumor samples. 

Our group has focused on leveraging supernatant samples from patient’s cytology specimens to extract nucleic acids that can be used to perform next generation sequencing. By repurposing an otherwise discarded substrate, we can now offer patients who do not have adequate tumor samples an alternative testing option that allows for treatment decisions without the need for an additional repeat biopsy. 

We have demonstrated the feasibility of this testing option in several studies and have recently published the analytical validation of a rapid one-day NGS assay using an otherwise discarded byproduct of cytologic specimen processing, making the reality of precision medicine available to more patients. 

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Explore Pathology Infectious Disease

The Viral Frontier

January 23, 2024

1 min read

Explore Pathology Genetics and epigenetics

Breathing New Life into Diagnostics

January 22, 2024

6 min read

Explore Pathology Analytical science

Opening a Window into Brain Trauma

January 18, 2024

4 min read

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.